Organogenesis (ORGO) applauds the Centers for Medicare & Medicaid Services’, CMS, proposed new payment approach for skin substitutes/cellular and tissue-based products, CTPs, under the CY 2026 Physician Fee Schedule and urges CMS to establish 2026 payment rates based on clinical value and relative cost.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG
- Organogenesis, MiMedx fall after CMS rule to cut skin substitutes spending
- Organogenesis Holdings Approves Key Proposals at Annual Meeting
- Buy Rating for Organogenesis: Favorable Medicare Pricing and Attractive Valuation Signal Growth Potential
- Hold Rating Maintained for Organogenesis Holdings Amid Uncertainty in Coverage and Sales Projections